24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
Losing Sense of Smell Can Worsen Life in Many Ways: StudyCoronavirus Cases Top 2,700 in China, While 5th U.S. Case Is ConfirmedGene Test Might Spot Soccer Players at High Risk for Brain TroubleMany Americans in the Dark About Eye HealthFirst Clinical Studies Find Wuhan Virus Closely Resembles SARSA Flu Shot May Spare Your Young Child a Hospital VisitMany of America's Most Critical Workers Are Short on Their ZzzsFaulty Immune System May Lead to Lung CancerOnly 1 in 4 Older Cardiac Patients Get Rehab TherapyPrescription-Strength Steroid Creams Sold Over-the-Counter Can Be DangerousWhat You Need to Know Now About the Wuhan VirusThe Damage of Vaccine MisinformationAHA News: What's Blood Type Got to Do With Clot Risk?Racism Linked to Faster Aging Among BlacksScientists Trace Coronavirus Outbreak to SnakesBlacks, Hispanics More Likely to Have Better Outcome After 'Bleeding' StrokeNew Drug Could Help Stop Blindness From Thyroid Eye Disease'Yo-Yo' Blood Pressure Numbers in Youth a Bad Sign for Health LaterFlame Retardants, Pesticides Remain Threat to U.S. Health: StudyDon't Want a 2nd Heart Attack? Lose the Belly FatHow to Keep Those Blood Vessels PumpingScreening for Chinese Coronavirus to Start at 3 Major Airports: CDCDo You Take Warfarin? Time of Day Might Not MatterHealth Tip: Signs of Food PoisoningSepsis Causes Far More Deaths Worldwide Than ThoughtMillennials Most Likely to Skip Flu Shot, Believe 'Anti-Vaxxer' Claims: PollResearchers Alter Mosquitoes to Resist Dengue InfectionMany Americans Are Inactive, With Southerners Faring WorseVirtual Reality Can Bring Real-Life PainAre Doctors Discarding 'Injured' Kidneys That Might Be Used for Transplant?Nerve Stimulation Therapy Could Cut Fibromyalgia PainWhich Obesity Surgery Is Right for You?Brake Dust Another Driver of Air PollutionWhat Works Best to Help Men With Overactive Bladder?More Studies Link Vaping to Asthma, COPDCertain Diabetes Meds May Lower Gout Risk, TooHeart Transplants From Donors With Hepatitis C May Be Safe: StudyClimate Change May Translate Into More Fatal InjuriesAll in the Timing: Many Get Knee Replacement Too Late or Too SoonHealth Tip: Preparing for an UltrasoundLow Levels of Key Blood Cells Could Signal Higher Death RiskGyms Are Fertile Ground for GermsTwo More Heartburn Meds Recalled Due to Possible CarcinogenZika Damage Showing Up in Babies Deemed 'Normal' at BirthHealth Tip: Coping With Winter NosebleedsHeart Disease May Up Risk of Kidney FailureFlu Cases Surge Early, Could a Tough Season Lie Ahead?Cluster of Unhealthy Risk Factors Could Raise Odds of Recurrent Blood ClotsAHA News: Worried About Dementia? Check This Blood Pressure NumberNew Study Reports Alarming Surge in E-Scooter Accidents
Questions and AnswersLinks
Related Topics

Diabetes

Nourianz Approved to Treat 'Off' Episodes in Parkinson Disease


HealthDay News
Updated: Aug 28th 2019

new article illustration

WEDNESDAY, Aug. 28, 2019 (HealthDay News) -- Nourianz (istradefylline) tablets have been approved as an add-on treatment to levodopa/carbidopa for adults with Parkinson disease experiencing "off" episodes, the U.S. Food and Drug Administration announced yesterday.

The drug is available in 20-mg or 40-mg doses, but the maximum recommended dosage in patients taking CYP3A4 inhibitors and those with moderate hepatic impairment is 20 mg once daily. The safety information for Nourianz states that use of the drug should be avoided in these patient populations.

Data from four 12-week placebo-controlled clinical studies demonstrated the effectiveness of Nourianz, a selective adenosine A2A receptor antagonist, in treating "off" episodes in 1,143 PD patients who were receiving treatment with levodopa/carbidopa. Compared with patients who received placebo, patients who received Nourianz experienced a statistically significant decrease in daily "off" time from baseline.

The most commonly reported adverse reactions with Nourianz included dyskinesia, dizziness, constipation, nausea, hallucination, and insomnia. The FDA noted that physicians should monitor patients for development or progression of dyskinesia while taking Nourianz. A reduction in dosage or stoppage of Nourianz should be considered in the case of hallucinations, psychotic behavior, or impulsive/compulsive behavior. Nourianz should not be used during pregnancy, and women with childbearing potential should use contraception during treatment.

Approval was granted to Kyowa Kirin.

More Information